Ms. Christina Cameron reports

ANTIBE ANNOUNCES TSX DELISTING REVIEW

Antibe Therapeutics Inc. has been informed by its regulator, the Toronto Stock Exchange, that the TSX is reviewing the eligibility for continued listing on the exchange. The TSX has identified the company's financial condition as a criterion for delisting applicable to the company.

Antibe has been invited to make submissions to TSX and a hearing has been scheduled for the afternoon of April 23, 2024. Further updates will be provided as appropriate.

The company also confirms that it is no longer quoted on the OTCQX.

About Antibe Therapeutics Inc.

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target pain and inflammation arising from a wide range of medical conditions.

We seek Safe Harbor.